AR130935A1 - Compuestos de cnp - Google Patents

Compuestos de cnp

Info

Publication number
AR130935A1
AR130935A1 ARP230102924A ARP230102924A AR130935A1 AR 130935 A1 AR130935 A1 AR 130935A1 AR P230102924 A ARP230102924 A AR P230102924A AR P230102924 A ARP230102924 A AR P230102924A AR 130935 A1 AR130935 A1 AR 130935A1
Authority
AR
Argentina
Prior art keywords
compounds
cnp
medicaments
novel
pharmaceutical compositions
Prior art date
Application number
ARP230102924A
Other languages
English (en)
Inventor
Jakob Ewald Rasmussen
Kodal Anne Louise Bank
Jonas Alfred Karl Wilbs
Christian Poulsen
Peter Madsen
Frieboes Kilian Waldemar Conde
Christian Wenzel Torne
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR130935A1 publication Critical patent/AR130935A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta solicitud se refiere a nuevos compuestos del péptido natriurético tipo C (CNP), composiciones farmacéuticas que comprenden estos compuestos y estos compuestos para su uso como medicamentos.
ARP230102924A 2022-11-02 2023-11-01 Compuestos de cnp AR130935A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22205128 2022-11-02

Publications (1)

Publication Number Publication Date
AR130935A1 true AR130935A1 (es) 2025-02-05

Family

ID=84364215

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102924A AR130935A1 (es) 2022-11-02 2023-11-01 Compuestos de cnp

Country Status (10)

Country Link
US (1) US12077561B2 (es)
JP (1) JP2025521254A (es)
KR (1) KR20240172760A (es)
CN (1) CN120152985A (es)
AR (1) AR130935A1 (es)
AU (1) AU2023374630A1 (es)
CO (1) CO2025005678A2 (es)
IL (1) IL320111A (es)
TW (1) TW202419463A (es)
WO (1) WO2024094747A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119529033A (zh) * 2024-12-02 2025-02-28 中山大学 一种用于npr-b靶向的超长效多肽及其在骨骼系统病症中的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2073751T3 (es) 1990-04-20 1995-08-16 Hisayuki Matsuo Nuevo peptido con actividad fisiologica de origen porcino.
JP3026354B2 (ja) 1990-09-27 2000-03-27 壽之 松尾 ヒトｃｎｐ遺伝子及び前駆体蛋白
JP2809533B2 (ja) 1991-01-31 1998-10-08 壽之 松尾 Ｃｎｐ類似体ペプチド
WO2000071576A2 (en) 1999-05-24 2000-11-30 Mayo Foundation For Medical Education And Research Adenovirus vectors encoding brain natriuretic peptide
US6407211B1 (en) 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
IL142118A0 (en) 2001-03-20 2002-03-10 Prochon Biotech Ltd Method and composition for treatment of skeletal dysplasias
WO2005000095A2 (en) 2003-06-20 2005-01-06 Mayo Foundation For Medical Education And Research Isoforms of brain natriuretic peptide
DE202004018921U1 (de) 2004-12-06 2005-02-17 Eppendorf Ag Mikrotiterplatte
BRPI0716228A2 (pt) 2006-09-08 2013-10-15 Mayo Foundation Polipeptídeos aquaréticos e natriuréticos carecendo de atividade vasodilatadora
EP2765139B1 (en) 2007-07-20 2017-04-12 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
AU2008326327A1 (en) * 2007-11-21 2009-05-28 Biomarin Pharmaceutical Inc. Variants of C-type natriuretic peptide
WO2009086126A2 (en) 2007-12-21 2009-07-09 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
WO2009149161A2 (en) 2008-06-06 2009-12-10 Mayo Foundation For Medical Education And Research Chimeric natriuretic polypeptides and methods for inhibiting cardiac remodeling
US8455438B2 (en) 2008-12-29 2013-06-04 Mayo Foundation For Medical Education And Research Natriuretic polypeptides for reducing or preventing restenosis
JP2012518029A (ja) 2009-02-19 2012-08-09 ノヴォ・ノルディスク・アー／エス 第ｖｉｉｉ因子の修飾
US20120053123A1 (en) 2009-05-05 2012-03-01 Mayo Foundation For Medical Education And Research Natriuretic polypeptides having mutations within their disulfide rings
TWI471137B (zh) 2009-05-20 2015-02-01 Biomarin Pharm Inc Ｃ型利鈉胜肽變異體
WO2012088608A1 (en) 2010-12-27 2012-07-05 Enobia Canada Limited Partnership Compositions comprising natriuretic peptides and methods of use thereof
EP2666475B1 (en) 2011-01-21 2017-08-16 Igisu Co., Ltd. Therapeutic agent for alopecia
CN107090028A (zh) 2011-08-30 2017-08-25 梅约医学教育与研究基金会 利钠多肽
CA2852874A1 (en) 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US20150293119A1 (en) 2011-12-23 2015-10-15 Mayo Foundation For Medical Education And Research Assessing renal structural alterations and outcomes
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US8835601B2 (en) 2012-12-21 2014-09-16 Mayo Foundation For Medical Education And Research Natriuretic polypeptide delivery systems
EP2956160B1 (en) 2013-02-15 2018-04-25 Mayo Foundation For Medical Education And Research Insulin secreting polypeptides
US20140274901A1 (en) 2013-03-12 2014-09-18 Mayo Foundation For Medical Education And Research Proanp compositions and methods for treating acute heart failure
DE102014213506A1 (de) 2014-07-11 2016-01-14 Robert Bosch Gmbh Wicklungselement für eine Axialflussmaschine, Statoreinheit für eine Axialflussmaschine sowie Verfahren zur Herstellung einer Statoreinheit für eine Axialflussmaschine
MX2017008915A (es) 2015-01-09 2018-04-26 Ascendis Pharma Growth Disorders As Profarmacos de peptido natriuretico tipo c (cnp).
AU2016298425B2 (en) 2015-07-30 2022-11-10 Biomarin Pharmaceutical Inc. Use of C-type natriuretic peptide variants to treat skeletal dysplasia
JP7104625B2 (ja) 2015-12-08 2022-07-21 バイオマリン ファーマシューティカル インコーポレイテッド 骨関節炎を処置するためのｃ型ナトリウム利尿ペプチド変異体の使用
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
RS63793B1 (sr) 2016-01-08 2022-12-30 Ascendis Pharma Growth Disorders As Cnp prolekovi kod kojih je nosač povezan sa cikličnom komponentom
IL259827B2 (en) 2016-01-08 2025-07-01 Ascendis Pharma Growth Disorders As Controlled-release CNP agonists with low initial NPR-B activity
EP3400021A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Controlled-release cnp agonists with low npr-c binding
BR112018011152A2 (pt) 2016-01-08 2018-11-21 Ascendis Pharma Growth Disorders As agonistas de cnp de liberação controlada com estabilidade em nep aumentada
AU2017205273C1 (en) 2016-01-08 2022-12-01 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
JP7126270B2 (ja) * 2017-03-22 2022-08-26 ファーマイン コーポレイション Ｎｐｒａアゴニスト、組成物およびその使用
EP3553079A1 (en) 2018-04-12 2019-10-16 Bayer Aktiengesellschaft C-type natriuretic peptide engrafted antibodies
MX2021008708A (es) 2019-02-11 2021-09-21 Ascendis Pharma Growth Disorders As Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp).
CN114616242A (zh) 2019-09-16 2022-06-10 生物马林药物股份有限公司 Cnp变体和其共轭物
PH12022553410A1 (en) * 2020-06-12 2024-04-22 Pharmain Corp C-type natriuretic peptides and methods thereof in treating cancer
KR20230024352A (ko) * 2020-06-12 2023-02-20 파마인 코포레이션 C형 나트륨이뇨 펩타이드 및 이의 급성 폐 손상의 치료에서의 방법

Also Published As

Publication number Publication date
TW202419463A (zh) 2024-05-16
WO2024094747A1 (en) 2024-05-10
KR20240172760A (ko) 2024-12-10
JP2025521254A (ja) 2025-07-08
CO2025005678A2 (es) 2025-05-19
US12077561B2 (en) 2024-09-03
US20240209028A1 (en) 2024-06-27
IL320111A (en) 2025-06-01
CN120152985A (zh) 2025-06-13
AU2023374630A1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
CO2025005678A2 (es) Compuestos de cnp
CO2020009997A2 (es) Composiciones sólidas que comprenden un agonista de glp-1, una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
CO2022004335A2 (es) Variantes del cnp y sus conjugados
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
BR112018001761A2 (pt) uso de variantes de peptídeo natriurético tipo c para tratar a displasia esquelética
AR104984A1 (es) Compuestos selectivos para pyy y sus usos
AR069136A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 (peptido somilar al glucagon tipo 1) y usos de los mismos
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
CL2011003173A1 (es) Análogo del glucagón, agonista gip y glp-1; dímero que comprende el análogo de glucagón; conjugado con el análogo; composición que comprende dicho análogo; uso para preparar un medicamento para tratar diabetes, reducir el aumento de peso o inducir la pérdida de peso.
CL2008000669A1 (es) Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras.
CO2018012002A2 (es) Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
ECSP21088669A (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
ECSP21082195A (es) Formas sólidas de un inhibidor de glyt1
CO2021005915A2 (es) Composiciones estables de semaglutida y usos de las mismas
BR112021006280A2 (pt) terapias imunoablativas
MX2023009011A (es) Inhibidor de cdk.
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2022005669A (es) Adsorbente de baja emision.
MX2023006284A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
CO2022016754A2 (es) Moléculas de fijación para el tratamiento de cáncer
MX2023006281A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
MX2023006280A (es) Composicion farmaceutica de agonistas duales de glp-1/glp-2.
CL2024002379A1 (es) Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso